Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation

Rheumatology (United Kingdom)

Volumn 53, Issue 3, 2014, Pages 433-437

  Aggarwal, Rohit ^a   Oddis, Chester V ^a   Goudeau, Danielle ^a   Fertig, Noreen ^a   Metes, Ilinca ^a   Stephens, Chad ^a   Qi, Zengbiao ^a   Koontz, Diane ^a   Levesque, Marc C ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anti transcription intermediary factor 1 gamma (TIF1 ) autoantibody; Development and validation of quantitative measure; ELISA; Idiopathic inflammatory myopathy; Immunoprecipitation

Indexed keywords

ANTI-TRANSCRIPTION INTERMEDIARY FACTOR 1-GAMMA (TIF1-Γ) AUTOANTIBODY; DEVELOPMENT AND VALIDATION OF QUANTITATIVE MEASURE; ELISA; IDIOPATHIC INFLAMMATORY MYOPATHY; IMMUNOPRECIPITATION;

AREA UNDER CURVE; AUTOANTIBODIES; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MYOSITIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION FACTORS;

EID: 84894360265     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket383     Document Type: Article

References (12)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:403-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
3. Trallero-Araguas E, Rodrigo-Pendas JA, Selva-O'Callaghan A et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum 2012;64:523-32.
4. Fujimoto M, Hamaguchi Y, Kaji K et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum 2012;64:513-22.
5. Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A et al. Anti-TIF1gamma antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis 2012;71:993-6.
6. Okano Y, Medsger TA Jr. Novel human autoantibodies reactive with 5'-terminal trimethylguanosine cap structures of U small nuclear RNA. J Immunol 1992;149:1093-8.
7. Mitri GM, Lucas M, Fertig N et al. A comparison between anti-Th/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 2003;48:203-9.
8. Chinoy H, Fertig N, Oddis CV et al. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.
9. Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep 2006;8:196-203.
10. Targoff IN, Mamyrova G, Trieu EP et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006;54:3682-9.
11. Vincent DF, Yan KP, Treilleux I et al. Inactivation of TIF1gamma cooperates with Kras to induce cystic tumors of the pancreas. PLoS Genet 2009;5: e1000575.
12. Gunawardena H, Wedderburn LR, North J et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology 2008;47:324-8.